Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot

We study the real-life effect of an unprecedented rapid mass vaccination campaign. Following a large outbreak of the Beta variant in the district of Schwaz/Austria, 100,000 doses of BNT162b2 (Pfizer/BioNTech) were procured to mass vaccinate the entire adult population of the district between the 11t...

Descripción completa

Detalles Bibliográficos
Autores principales: Paetzold, Jörg, Kimpel, Janine, Bates, Katie, Hummer, Michael, Krammer, Florian, von Laer, Dorothee, Winner, Hannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807735/
https://www.ncbi.nlm.nih.gov/pubmed/35105889
http://dx.doi.org/10.1038/s41467-022-28233-8
_version_ 1784643747681665024
author Paetzold, Jörg
Kimpel, Janine
Bates, Katie
Hummer, Michael
Krammer, Florian
von Laer, Dorothee
Winner, Hannes
author_facet Paetzold, Jörg
Kimpel, Janine
Bates, Katie
Hummer, Michael
Krammer, Florian
von Laer, Dorothee
Winner, Hannes
author_sort Paetzold, Jörg
collection PubMed
description We study the real-life effect of an unprecedented rapid mass vaccination campaign. Following a large outbreak of the Beta variant in the district of Schwaz/Austria, 100,000 doses of BNT162b2 (Pfizer/BioNTech) were procured to mass vaccinate the entire adult population of the district between the 11th and 16th of March 2021. This made the district the first widely inoculated region in Europe. We examine the effect of this campaign on the number of infections, cases of variants of concern, hospital and ICU admissions. We compare Schwaz with (i) a control group of highly similar districts, and (ii) with populations residing in municipalities along the border of Schwaz which were just excluded from the campaign. We find large and significant decreases for all outcomes after the campaign. Our results suggest that rapid mass vaccination is an effective tool to curb the spread of SARS-CoV-2.
format Online
Article
Text
id pubmed-8807735
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-88077352022-02-07 Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot Paetzold, Jörg Kimpel, Janine Bates, Katie Hummer, Michael Krammer, Florian von Laer, Dorothee Winner, Hannes Nat Commun Article We study the real-life effect of an unprecedented rapid mass vaccination campaign. Following a large outbreak of the Beta variant in the district of Schwaz/Austria, 100,000 doses of BNT162b2 (Pfizer/BioNTech) were procured to mass vaccinate the entire adult population of the district between the 11th and 16th of March 2021. This made the district the first widely inoculated region in Europe. We examine the effect of this campaign on the number of infections, cases of variants of concern, hospital and ICU admissions. We compare Schwaz with (i) a control group of highly similar districts, and (ii) with populations residing in municipalities along the border of Schwaz which were just excluded from the campaign. We find large and significant decreases for all outcomes after the campaign. Our results suggest that rapid mass vaccination is an effective tool to curb the spread of SARS-CoV-2. Nature Publishing Group UK 2022-02-01 /pmc/articles/PMC8807735/ /pubmed/35105889 http://dx.doi.org/10.1038/s41467-022-28233-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Paetzold, Jörg
Kimpel, Janine
Bates, Katie
Hummer, Michael
Krammer, Florian
von Laer, Dorothee
Winner, Hannes
Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot
title Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot
title_full Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot
title_fullStr Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot
title_full_unstemmed Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot
title_short Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot
title_sort impacts of rapid mass vaccination against sars-cov2 in an early variant of concern hotspot
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807735/
https://www.ncbi.nlm.nih.gov/pubmed/35105889
http://dx.doi.org/10.1038/s41467-022-28233-8
work_keys_str_mv AT paetzoldjorg impactsofrapidmassvaccinationagainstsarscov2inanearlyvariantofconcernhotspot
AT kimpeljanine impactsofrapidmassvaccinationagainstsarscov2inanearlyvariantofconcernhotspot
AT bateskatie impactsofrapidmassvaccinationagainstsarscov2inanearlyvariantofconcernhotspot
AT hummermichael impactsofrapidmassvaccinationagainstsarscov2inanearlyvariantofconcernhotspot
AT krammerflorian impactsofrapidmassvaccinationagainstsarscov2inanearlyvariantofconcernhotspot
AT vonlaerdorothee impactsofrapidmassvaccinationagainstsarscov2inanearlyvariantofconcernhotspot
AT winnerhannes impactsofrapidmassvaccinationagainstsarscov2inanearlyvariantofconcernhotspot

Ejemplares similares